Abstract: The present invention relates to a pharmaceutical composition of (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, a process for the preparation thereof and its use in the treatment of diseases.
Type:
Application
Filed:
May 6, 2019
Publication date:
July 29, 2021
Applicant:
Oryzon Genomics, S.A.
Inventors:
Reto MAURER, Patrick BUSSON, Georg HUMMEL
Abstract: Various embodiments of modified-release multiparticulates (in bead or granule from) are described. The modified-release multiparticulates can comprise a core including a pharmaceutical and/or probiotic agent, optionally with additional excipients or binders to aid in creation of the core, one or more functional coatings disposed on the core and configured to provide a modified-release profile of the pharmaceutical and/or probiotic agent when given orally, and a coating of hypromellose acetate succinate (HPMCAS) disposed on the one or more functional coatings and configured to impart multiparticulate stability in aqueous acidic media. Suspensions including the modified-release multiparticulates are also described.
Type:
Application
Filed:
September 4, 2020
Publication date:
July 29, 2021
Inventors:
Robert Niichel, Samuel Reinhold, III, Clayton J. Nelsen, Dan A. Finkbeiner, Roy J. McDaniel, Andrew D. Padilla
Abstract: Cationic polymers are provided for delivering anionic active agents, preferably in the form or nanoparticles and other nanostructures. The polymer can be a polycation homopolymer or a copolymer containing a polycation block. The polycations and polycation containing polymers can contain dicarboxylic acid ester units and units of (?-amino acid)-?,?-alkylene diester units. The nanoparticles can contain high loadings of anionic active agents, with sustained release of the active agents. Methods of making the polycations and polycation containing polymers are provided. Methods of making the nanoparticles and formulating them for administration to an individual in need thereof are also provided.
Abstract: The present invention generally relates to particles, including nanocapsules or other nanoentities, comprising a polymer such as polysialic acid. The particles are able to access the interior of the cells, and/or to procure the intracellular release of the associated drugs. In 5 one aspect, the present invention is directed to nanocapsules or other entities having an exterior or surface comprising a polymer such as polysialic acid. In some cases, targeting moieties such as Lyp-1 or tLyp-1 peptide are bonded to the polymer, e.g., using aminoalkyl (C1-C4) succinimide or other linkers. These may be created, for example, by reacting a carboxylate moiety on a polymer with an aminoalkyl maleimide (C1-C4) or an aminoalkyl 10 (C1-C4) methacrylamide, and reacting the resulting aminoalkyl (C1-C4) maleimide or the aminoalkyl (C1-C4) methacrylamide to a cysteine or other sulfur group.
Type:
Application
Filed:
November 2, 2018
Publication date:
July 29, 2021
Applicant:
Universidade de Santiago de Compostela
Inventors:
María José Alonso Fernandez, Desireé Teijeiro Osorio, Carmen María Teijeiro Valiño, Ana Cadete Pires
Abstract: The present invention provides a drug-loaded tissue adhesive film, comprising alternately superposed cationic layers and anionic layers, at least one of the cationic layers and the anionic layers being a drug layer, or at least one of the cationic layers and the anionic layers containing a drug with charges. The provided drug-loaded tissue adhesive film has good tissue adhesiveness, biocompatibility, degradable absorption, and stability, and the physical and chemical properties of the drug-loaded tissue adhesive film can be adjusted by adjusting material compositions.
Abstract: A method for reducing skin sensitization of an asenapine-containing patch comprising a backing layer and an adhesive agent layer, the method comprising: using an adhesive agent for preparing the adhesive agent layer, the adhesive agent comprising free asenapine in a range of 2 to 5% by mass, isopropyl palmitate in a range of 5 to 12% by mass, styrene-isoprene-styrene block copolymer in a range of 10 to 20% by mass, polyisobutylene in a range of 3 to 10% by mass, alicyclic saturated hydrocarbon resin in a range of 50 to 70% by mass, and liquid paraffin in a range of 5 to 12% by mass, relative to a total amount of the adhesive agent; and preparing the asenapine-containing patch having an amount of the adhesive agent layer after drying in a range of 100 to 400 g/m2.
Abstract: The disclosure provides new medical device and manufacturing methods as well as chemicals that enhance delivery of pharmaceuticals from a transdermal patch, where the patch may include a film, adhesive, emulsifier, tackifier, or hydrogel.
Abstract: Disclosed herein are methods and compositions for treating a disease or disorder in a subject in need thereof. The methods may include administering to the subject a therapeutically effective amount of a GPR37 agonist. The disease or disorder may be selected from inflammation, inflammatory pain, chronic pain, viral infection, bacterial infection, malaria, sepsis, or a combination thereof.
Abstract: A method of treating an ocular, inflammatory, immune, and/or metabolic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a compound having a structure of formula (I).
Type:
Application
Filed:
June 7, 2019
Publication date:
July 29, 2021
Inventors:
Marcin Bernard GOLCZAK, Josie Ann SILVAROLI
Abstract: Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C?C—, (a tolan), —CH?CH— (a stilbene, preferably tram); or —CRa?CRb— a stilbene derivative; where Ra and Rb are independently H or phenyl optionally substituted with —(R3)p or —(R4)q; R1 to R4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3?, 4, 4?, and/or 5, 5?; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ?1. Each R1 to R2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein.
Type:
Application
Filed:
April 2, 2021
Publication date:
July 29, 2021
Applicant:
BioMendics, LLC
Inventors:
Chun-che Tsai, Karen M. McGuire, James M. Jamison, Jack L. Summers
Abstract: The present invention discloses a system and method for preparing and delivering various precursor compositions as a replacement therapy for testosterone and other hormone deficiencies that naturally occur with aging in canines and other domesticated animals. Precursor compositions are selected and designed for the purpose of formulating non-toxic therapeutic hormone supplement for oral consumption. The invention features low dose continuous supplementation to be incorporated with daily meals. The process of the present invention delivers an orally ingested substance, e.g., a food, supplement, treat, etc., that contains an anti-aging formulation comprising a hormone precursor (prohormone) that is absorbed by the digestive system and secreted into the bloodstream with a second substance to facitate its ingestion, absorption and delivery to the body's tissues.
Abstract: The present invention relates to the use of diluted, thus non-sclerosing, polidocanol solutions as immunomodulating and anti-inflammatory agents. The inventions further relates to non-sclerosing compositions 5 comprising polidocanol in concentration of from 0.03 to 0.10 % w/V for the treatment of psoriatic skin rashes, for cosmetic use and for the reduction of peripheral venous stasis.
Abstract: The present invention relates to a surfactant, or a pharmaceutically acceptable salt of a surfactant or a stereoisomer of a surfactant, and a pharmaceutical composition including the surfactant, for the treatment of conditions of the cervix/anogenital region and non-melanoma skin cancers (NMSCs). The composition may comprise an anionic or amphoteric surfactant, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the surfactant comprises: a hydrophilic moiety selected from the group consisting of a carbonate, a sulfonate, and a sulfate; and at least one pharmaceutically acceptable excipient. Methods of using the surfactant and composition are also disclosed.
Abstract: Disclosed herein are storage-stable ephedrine single-phase solution compositions, comprising 4 mg/mL to 6 mg/mL of ephedrine, a pH adjuster comprising acetic acid, and water, wherein the composition has a pH between 4.5 and 5.0; and wherein the pH drift of the composition is less than 0.5 after storage over at least two months at 25° C. and 60% relative humidity. Also disclosed herein are methods of making and using the same.
Type:
Application
Filed:
November 12, 2020
Publication date:
July 29, 2021
Applicant:
Nevakar Inc.
Inventors:
Irfan Ali Mohammed, Tushar Hingorani, Kumaresh Soppimath
Abstract: A ready-to-administer antioxidant free phenylephrine compositions has improved stability and is optionally free of metal chelating agents. Contemplated compositions are preferably packaged into a flexible polymer bag and maintain degradation of the phenylephrine at remarkably low levels, even over extended storage periods.
Abstract: Compounds of Formula I or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided.
Type:
Application
Filed:
March 29, 2021
Publication date:
July 29, 2021
Inventors:
Sreenivasarao Vepachedu, Hans J. Moebius, Anton Bespalov
Abstract: The present invention includes a method for using diNACA as a prodrug to deliver diNACA, NACA and NAC to a mammal for therapeutic purposes to prevent or treat diseases or disorders involving oxidative stress. The method includes any disease that involves the therapeutic use of NACA or NAC as a therapeutic agent. Also, compositions and methods for the prevention, reduction or treatment of corneal endothelial cell loss in a patient that comprise providing the patient with an amount of at least one, alone or in combination, of N-acetylcysteine amide (NACA) or (2R,2R?)-3,3?-disulfanediyl bis(2-acetamidopropanamide) (diNACA) (diNACA) to prevent or reduce the corneal endothelial cell loss or to prevent or treat presbyopia. DiNACA can be used to prevent or treat cataracts.
Abstract: The present invention relates to hydroxy-substituted amino and ammonium derivatives, in particular the compounds of formula 1 or 2, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder.
Type:
Application
Filed:
March 19, 2021
Publication date:
July 29, 2021
Inventors:
Georg Schlechtingen, Hans-Joachim Knolker, Tim Friedrichson, Gary Jennings, Tobias Braxmeier
Abstract: The present application relates to a method of increasing the volume of an airway surface liquid (ASL) layer and/or increasing mucociliary clearance in a subject. For example, the application relates the use of one or more neuronal agonists such as menthol and/or capsaicin, in combination with hypertonic saline (HTS) or isotonic saline (ITS) for increasing the volume of airway surface liquid (ASL) and/or increasing mucociliary clearance or for treatment of a disease, disorder or condition treatable by increasing the volume of an ASL layer and/or increasing mucociliary clearance. For example, the disease, disorder or condition is cystic fibrosis or a non-cystic fibrosis respiratory disease, disorder or condition such as non-cystic fibrosis bronchiectasis.
Type:
Application
Filed:
January 22, 2021
Publication date:
July 29, 2021
Inventors:
Juan P. Ianowski, Julian S. Tam, Xiaojie Luan, Veronica A. Campanucci
Abstract: Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.
Type:
Application
Filed:
March 16, 2021
Publication date:
July 29, 2021
Inventors:
Imran Alibhai, Sofia De Achaval, Beverly C. Langevin, Tian Zhou
Abstract: A non-crystallizing blend includes cannabidiol (CBD) and cannabidiolic acid (CBDA). A method of forming a non-crystallizing blend of CBD and CBDA includes obtaining a CBD isolate including at least 80% by weight CBD, obtaining a CBDA isolate including at least 80% by weight CBDA, and combining and mixing the CBD isolate and the CBDA. A method of treating a condition includes administering a therapeutically effective amount of a non-crystallizing blend of CBD and CBDA to a patient in need thereof.
Type:
Application
Filed:
January 26, 2021
Publication date:
July 29, 2021
Inventors:
Andrew HORVATH, Scott DAVIS, Matthew MOORE, Josh ELDRIDGE, James HOOK, William LANIER
Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Type:
Application
Filed:
April 14, 2021
Publication date:
July 29, 2021
Applicant:
Infirst Healthcare Limited
Inventors:
Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
Abstract: The present disclosure provides a method of preventing or treating anti-NMDAR encephalitis in a subject in need thereof, including administering to the subject an effective amount of benzoic acid or a salt and derivative thereof.
Abstract: This patent application discloses a method of manufacturing eye drops that can be used to ameliorate or cure eye conditions such as cataracts, presbyopia, glaucoma, astigmatism, dry eye as well as for generic eye care uses. The sole active ingredient of said eye drops is citric acid—its aqueous solution around 0.9% by weight, which can be adjusted to either higher or lower levels of concentration according to clinical needs. Citric acid can be sourced either from industrial products or from natural fruits such as lemons and pineapples.
Abstract: The present invention relates to a pharmaceutical composition comprising a citrate salt for use in enhancing the effect of an anticancer drug.
Abstract: The present invention relates to the field of seizures. More specifically, the present invention provides compositions and methods for treating refractory seizures in neonates. In one embodiment, the method comprises the steps of (a) administering to the patient an amount of a KCC2 agonist and/or trkB antagonist effective to restore KCC2 expression to normal physiological levels; and (b) administering to the patient an effective amount of an anti-seizure medication.
Abstract: The present disclosure provides methods of treating Alzheimer's Disease (AD) and rescuing cognitive deficits associated with AD in a subject having an apoE4/4 genotype, by administering a therapeutically effective amount of the loop-diuretic bumetanide to the subject. Also disclosed are kits for performing the method, including one or more doses of a bumetanide formulation; and which may also include instructions for treating a patient having an apoE4/4 genotype by administering bumetanide, and/or instructions and reagents for testing/identifying a subject having an apoE4/4 genotype.
Type:
Application
Filed:
April 12, 2019
Publication date:
July 29, 2021
Inventors:
Yadong Huang, Alice Taubes, Phil Nova, Marina Sirota
Abstract: To provide a compound used for activating autophagy, which has few side effects and mild effects. An autophagy activating agent comprising S1PC or a salt thereof as an active ingredient.
Abstract: One object of the present invention is to provide an inhibitor for renal injuries induced by an iodinated contrast medium. In this invention, cilastatin or a pharmaceutically acceptable salt thereof is used.
Type:
Application
Filed:
April 26, 2019
Publication date:
July 29, 2021
Inventors:
Akihiko SAITO, Sawako GOTO, Yoshiaki HIRAYAMA, Sakari SEKINE
Abstract: The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-OHEPA.
Type:
Application
Filed:
September 16, 2020
Publication date:
July 29, 2021
Inventors:
Jonathan Rowe, Kevin Duffy, John Climax
Abstract: Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
Type:
Application
Filed:
February 3, 2021
Publication date:
July 29, 2021
Inventors:
Kenneth C. Cundy, Sami Karaborni, Peter A. Virsik
Abstract: A composition effective for treating or preventing a condition for which extended exposure to ketones is beneficial contains medium chain triglycerides (MCTs) and also contains proteins in a weight ratio of at least 0.1 g protein/1.0 g of the compound. Other aspects are directed to a method of extending blood exposure to ketones derived from oral absorption of a food product by an individual; a method of improving or maintaining at least one of neurologic health, cognitive function, or exercise performance; and a method of making the composition.
Type:
Application
Filed:
July 9, 2019
Publication date:
July 29, 2021
Inventors:
Bernard Cuenoud, Stephen Cosgrave Cunnane
Abstract: Busulfan composition contains Busulfan and cyclodextrin in a weight ratio of 1-20:100-2000. The Busulfan composition is preferably prepared by following steps of: dissolving Busulfan in an organic solvent to obtain a Busulfan solution with a concentration of 1-20 mg/mL; dissolving SBE-?-cyclodextrin with water for injection to obtain 10-40% (w/v) aqueous solution of SBE-beta-cyclodextrin; mixing the two solutions under nitrogen atmosphere by stirring for 1 hour, and removing the organic solvent; and filtering and freeze drying the mixed solution. According to the present invention, the method can be used for tablets and injections.
Abstract: A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer.
Abstract: The present invention pertains to a group of taxane-lipid-polysaccharide dual conjugates of the Formula I, a process for the preparation thereof, uses thereof, and pharmaceutical compositions comprising the same. The invention also relates to a series of intermediates for the preparation of taxane-lipid-polysaccharide dual conjugates, a process for their preparation, and their use as drug delivery vehicles.
Type:
Application
Filed:
June 20, 2019
Publication date:
July 29, 2021
Inventors:
Jinghua Hu, Xiaohai Li, Yikang Shi, Si Wang, Hui Wang, Ang Zha, Fengyi Cui, Anny Wang, Daisy J. Li, Taining Zhang, Haijun Cheng
Abstract: Disclosed are methods of treating autism spectrum disorder (ASD) by administering a therapeutically effective amount of an isoprenoid antibiotic to subjects identified with a splicing defect in an ASD associated gene. The method of treating a subject with a neurological disease is carried out by identifying the subject comprising a splicing defect in an autism spectrum disorder (ASD)-associated gene, the target gene being characterized as having an hnRNP L binding site. The subject is treated by administering a spliceopathy rescue agent to repair the splicing defect. Also disclosed are methods of upregulating hnRNP L and hnRNP L targets by administering a therapeutically effective amount of an isoprenoid antibiotic. Methods of screening compounds for use in treating autism spectrum disorder (ASD) are also described.
Type:
Application
Filed:
June 5, 2019
Publication date:
July 29, 2021
Inventors:
Isabelle Draper, Alan S. Kopin, Donna Slonim
Abstract: This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
Abstract: The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.
Type:
Application
Filed:
November 10, 2020
Publication date:
July 29, 2021
Inventors:
Maximilian von EYNATTEN, Uli Christian BROEDL, Hans-Juergen WOERLE
Abstract: The present invention provides self-emulsifying, high concentration and high dose cannabinoid compositions and formulations, to improve administration of cannabinoids and standardized marijuana extracts to patients.
Abstract: Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or treating disease and disorders such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are listed in Tables 2, 4 and 5, and/or are represented by Formulae I, IV, V and VI, as defined in the specification. Methods utilizing these compounds are also provided.
Type:
Application
Filed:
March 29, 2021
Publication date:
July 29, 2021
Applicant:
Biokine Therapeutics Ltd.
Inventors:
Amnon PELED, Michal ABRAHAM KARNI, Orly EIZENBERG
Abstract: Apparatuses, methods, and systems for extraction, isolation, purification, and conversion of various cannabinoids, and modifications of whole-plant hemp extracts therewith are presented. A method for preparing a whole-plant hemp extract based product includes extracting cannabinoids from plant materials, such as one or more hemp varieties of Cannabis sativa. The method also includes separating and purifying CBD from the extracted cannabinoids, converting purified CBD to ?9-THC and ?8-THC and concurrently converting ?9-THC to CBN, purifying and separating the CBN, and combining the purified CBN with a whole-plan hemp extract. Products and supplements related to the method are also described.
Type:
Application
Filed:
April 15, 2021
Publication date:
July 29, 2021
Applicant:
Charlotte's Web, Inc.
Inventors:
Alexander Michael MCCORKLE, Graham Taylor CARLSON, Shelby Renee SHEAHAN
Abstract: A material which promotes ammonia metabolism in the body, as well as a material which has excellent ammonia metabolism improving effect and is effective for endurance enhancement and anti-fatigue are provided. An ammonia metabolism promoting agent, comprising catechins as an active ingredient. An agent for preventing or ameliorating hyperammonemia, hepatic encephalopathy or chronic fatigue syndrome, comprising catechins compound as an active ingredient. An ammonia metabolism promoting agent, an endurance enhancing agent and an anti-fatigue agent, comprising catechins, citrulline and arginine as active ingredients.
Abstract: Compositions including the combination of cremastranone analogs and anti-angiogenic agents and the use of the compositions for targeting ocular angiogenesis such as seen in neovascular eye diseases are disclosed.
Abstract: Methods of using compounds to inhibit ocular disease are disclosed herein. Methods are disclosed for inhibiting soluble epoxide hydrolase (sEH) for the treatment of ocular diseases, and in particular, wet age-related macular degeneration (AMD).